

Sally Baron-Hay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7060182/publications.pdf>

Version: 2024-02-01

14
papers

358
citations

1163117

8
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

565
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated Serum Insulin-Like Growth Factor Binding Protein-2 as a Prognostic Marker in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 1796-1806.	7.0	103
2	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
3	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , 2017, 25, 3485-3493.	2.2	59
4	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , 2017, 128, 1166-1175.	1.5	50
5	Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. <i>Supportive Care in Cancer</i> , 2020, 28, 4459-4466.	2.2	19
6	Electrophysiological and phenotypic profiles of taxane-induced neuropathy. <i>Clinical Neurophysiology</i> , 2020, 131, 1979-1985.	1.5	14
7	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trialâ€™Clinical outcomes and molecular determinants of response. <i>PLoS ONE</i> , 2019, 14, e0210891.	2.5	13
8	Frontline treatment of epithelial ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 1-16.	1.1	12
9	Evaluating the role of magnetic resonance imaging postâ€™neoadjuvant therapy for breast cancer in the <scp>NEONAB</scp> trial. <i>Internal Medicine Journal</i> , 2018, 48, 699-705.	0.8	9
10	Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). <i>Supportive Care in Cancer</i> , 2019, 27, 1309-1317.	2.2	6
11	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. <i>Pathology</i> , 2020, 52, 515-521.	0.6	5
12	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022, 82, GS1-01-GS1-01.	0.9	5
13	Breast Radiotherapy after Oncoplastic Surgeryâ€™A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 1685.	3.7	2
14	Pembrolizumab as adjuvant therapy in a patient with Lynch syndrome with synchronous mixed clear cell carcinoma of ovarian origin and endometrioid endometrial carcinoma. <i>BMJ Case Reports</i> , 2021, 14, e245497.	0.5	0